Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Sarcoma 5Carcinoma, Non-Small-Cell Lung 5Rhabdomyosarcoma 4Prostatic Neoplasms 4Osteosarcoma 3Neoplasms 3Sarcoma, Synovial 2Sarcoma, Ewing 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Lung Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenocortical Carcinoma 2Wilms Tumor 1Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Retinoblastoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neuroblastoma 1Mesothelioma, Malignant 1Liver Neoplasms 1Liposarcoma 1Leiomyosarcoma 1

Interventions

Cisplatin 24Carboplatin 19Paclitaxel 18pembrolizumab 12Gemcitabine 12Radiotherapy 9Fluorouracil 9Specimen Handling 8Magnetic Resonance Spectroscopy 7cemiplimab 6Platinum 6Nivolumab 6Docetaxel 6Cetuximab 61,2-diaminocyclohexaneplatinum II citrate 6epothilone B 5anlotinib 5Sunitinib 5Pemetrexed 5Oxaliplatin 5Everolimus 5Drug Therapy 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5durvalumab 4Radiotherapy, Intensity-Modulated 4Radiation 4Erlotinib Hydrochloride 4Celecoxib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma × cixutumumab × Clear all
NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed
43 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡